Literature DB >> 21555215

Phase 1 trials of molecular targeted therapies: are we evaluating toxicities properly?

Jean-Charles Soria.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21555215     DOI： 10.1016/j.ejca.2011.04.009

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  7 in total

1.  Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose.

Authors:  Maria-Athina Altzerinakou; Laurence Collette; Xavier Paoletti
Journal:  J Natl Cancer Inst       Date:  2019-11-01       Impact factor: 13.506

2.  Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials.

Authors:  Shing M Lee; Daniel Backenroth; Ying Kuen Ken Cheung; Dawn L Hershman; Diana Vulih; Barry Anderson; Percy Ivy; Lori Minasian
Journal:  J Clin Oncol       Date:  2016-02-29       Impact factor: 44.544

3.  Dose-finding designs for trials of molecularly targeted agents and immunotherapies.

Authors:  Cody Chiuzan; Jonathan Shtaynberger; Gulam A Manji; Jimmy K Duong; Gary K Schwartz; Anastasia Ivanova; Shing M Lee
Journal:  J Biopharm Stat       Date:  2017-02-06       Impact factor: 1.051

4.  Estimating global treatment toxicity burden from adverse-event data.

Authors:  Shing M Lee; Dawn L Hershman; Jieling Miao; Xiaobo Zhong; Joseph M Unger; Ying Kuen Ken Cheung
Journal:  Cancer       Date:  2017-11-07       Impact factor: 6.860

5.  Patient-reported tolerability of adverse events in phase 1 trials.

Authors:  Clémence Henon; Delphine Lissa; Xavier Paoletti; Constance Thibault; Christophe Le Tourneau; Emilie Lanoy; Antoine Hollebecque; Christophe Massard; Jean-Charles Soria; Sophie Postel-Vinay
Journal:  ESMO Open       Date:  2017-06-23

6.  Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities.

Authors:  Ricardo Costa; Rubens B Costa; Sarah M Talamantes; Irene Helenoswki; Benedito A Carneiro; Young Kwang Chae; William J Gradishar; Razelle Kurzrock; Francis J Giles
Journal:  Oncotarget       Date:  2017-06-29

7.  Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agents.

Authors:  Emma J Jordan; James Spicer; Debashis Sarker
Journal:  Oncotarget       Date:  2018-09-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.